Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide

What Was Tested

The paper reports a study of PT-141 (Bremelanotide) and Alpha-MSH, published as a randomized controlled trial.

Responder analyses are used to determine whether changes that occur during a clinical trial are clinically meaningful; for subjective endpoints such as those based on patient-reported outcomes (PROs), responder analyses are particularly useful.

Why It Was Studied

MCIDs for this study were based on changes from a single-blind phase to account for changes due to the placebo effect.

These analyses were restricted to a study population composed only of premenopausal women with a clinical diagnosis of HSDD and/or FSAD and were based on data from the same clinical trial.

Who Took Part

By PubMed's age tags, the people studied were adults, women only.

The prespecified analysis groups were all female sexual dysfunction (FSD)-based diagnoses (all study participants), those with HSDD alone, and a combined group of those with FSAD alone plus those with mixed HSDD/FSAD.

Post hoc analyses were also performed for subjects with mixed HSDD/FSAD with a primary diagnosis of HSDD.

How the Study Was Run

The researchers set it up as a randomized, double-blind, single-blind and placebo-controlled study.

Because people in this PT-141 (Bremelanotide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on PT-141 (Bremelanotide), so expectations could not easily colour the readings.

In this single-blind PT-141 (Bremelanotide) study one party knew the assignments and the other did not.

Some participants received a placebo instead of PT-141 (Bremelanotide), giving a reference point.

The responder analyses were performed for the change from baseline to end of study for a total of 7 endpoints.

What Was Measured

The subject headings attached to it are Libido, Peptides, Cyclic, Premenopause, Sexual Dysfunction, Physiological, Sexual Dysfunctions, Psychological, Surveys and Questionnaires and alpha-MSH.

Author keywords: Bremelanotide, Female Sexual Dysfunction, Hypoactive Sexual Desire Disorder, Minimal Clinically Important Difference and Responder Analyses.

What This Means in Plain Language

The paper is a randomized, double-blind and single-blind study of PT-141 (Bremelanotide) and Alpha-MSH.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2019 (The journal of sexual medicine), a journal based in Netherlands.

More context: the PT-141 (Bremelanotide) compound page and the Alpha-MSH compound page, all human trials.